02005 SSY GROUP
- 4.780
- +0.080+1.70%
SSY GROUP News
Shisi Pharmaceutical Group (02005.HK): Performance is in line with expectations, net profit margin increased year-on-year
Shisi Pharmaceutical Group (2005.HK): Strong growth in high-volume infusion sales and APIs
Shisi Pharmaceutical Group (02005.HK): Steady profit side growth, multiple business layout provides medium- to long-term growth drivers
Shisi Pharmaceutical Group (02005.HK): Performance is in line with expectations, gross margin increased year-on-year
Shisi Pharmaceutical Group (2005.HK): Large infusions lead growth and are optimistic that many sectors will blossom
Shisi Pharmaceutical Group (02005.HK): Performance is in line with expectations, and large infusions maintain a steady growth trend
Shisi Pharmaceutical Group (2005.HK): Steady growth in infusions, APIs and formulations wait for them to blossom
Shi Si Pharmaceutical Group (02005.HK): Large infusions, steady growth in oral formulations
Research Report Nuggets | Huatai Securities: Maintains the “buy” rating target price of HK$6.16 for Shizi Pharmaceutical Group
Shi Si Pharmaceutical Group (02005.HK): Continuously selected for national drug collection and oral formulation sector, the growth rate is fast
Shi Si Pharmaceutical Group (2005.HK): Major infusion recovery is considerable, demand for APIs or repair
Shisi Pharmaceutical Group (2005.HK): The sector with impressive infusion sales continues to fully blossom
Shisi Pharmaceutical Group (2005.HK): API companies stabilize diagnosis and treatment recovery and accelerate major infusions
Shisi Pharmaceutical Group (02005.HK): 2022 performance meets expectations, product structure continues to be optimized
Shisi Pharmaceutical Group (02005.HK): Net profit is in line with expectations, the API sector grew rapidly year-on-year
Changes in Hong Kong stocks | Shisiyao Group rose 4.6%, and brokerage firms are bullish on the company's target price to HK$5.6
Shisi Pharmaceutical Group (2005.HK): Weak performance in the third quarter of '22 was mainly affected by foreign exchange and weakening demand for caffeine
Shisi Pharmaceutical Group (2005.HK): APIs are still an important engine
Shisi Pharmaceutical Group (02005.HK): Net profit is in line with our expectations, API continues to grow rapidly
Shisi Pharmaceutical Group (2005.HK): APIs lead growth, rapid recovery of infusions
Analysis
Price Target
No Data
